Patents Examined by Terra Cotta Gibbs
  • Snornai-small nucleolar RNA degradation by RNA interference in trypanosomatids
    Patent number: 8338583
    Abstract: Polynucleotides and a method suitable for downregulation of small nuclear RNA which can be used to treat diseases associated with activity of small nuclear RNA are provided. Specifically, the present invention can be used to downregulate snoRNA molecules or box H/ACA-containing RNA molecules which are involved in diseases such as cancer.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: December 25, 2012
    Assignee: Bar-Ilan University
    Inventor: Shulamit Michaeli
  • Methods for nucleic acid transfer into cells
    Patent number: 8334272
    Abstract: The present invention provides methods for increasing the transfer of nucleic acids into cells. In particular, the present invention provides for the use of inhibitors of HDAC6, a cytoplasmic histone deacetylase present in mammalian cells by, for example, small molecules or siRNA treatment, in increasing gene transfer and/or expression in cells in vitro and in vivo for research and gene therapy applications.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: December 18, 2012
    Assignee: Northwestern University
    Inventors: David A. Dean, Robert Christopher Geiger
  • Compositions and methods for inhibiting expression of factor VII gene
    Patent number: 8334273
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: December 18, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Akin Akinc
  • Lactic acid bacteria-derived double-stranded RNA
    Patent number: 8334371
    Abstract: An immunoregulator that is safe and efficiently incorporated into cells along with a production process thereof are provided. Double-stranded RNA derived from lactic acid bacteria, an immunoregulator having for an active ingredient thereof double-stranded RNA derived from lactic acid bacteria, and a process for producing double-stranded RNA derived from lactic acid bacteria are provided. Bacteria cells of a strains of lactic acid bacteria such as genus Tetragenococcus, genus Pediococcus, genus Lactobacillus, genus Streptococcus or genus Leuconostoc are able to produce double-stranded RNA having immunoregulatory action therein.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: December 18, 2012
    Assignee: Kikkoman Corporation
    Inventors: Ikuko Masuda, Daisuke Kaneko, Tadaomi Kawashima, Noriko Tsuji, Akemi Kosaka
  • Modulation of factor 11 expression
    Patent number: 8334372
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 18, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski
  • Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
    Patent number: 8329891
    Abstract: Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that modulate ActRII signaling and cell adhesion. Agents are tested that modulate cell adhesion, detachment, invasion and viability. Agents that modulate the expression, phosphorylation, function and translocation of ActRII signaling pathway members also can predict agents that modulate cell adhesion, detachment, invasion and viability. The methods have utility in identifying agents that prevent cancer cell metastasis, wound dehiscence, aortic dissection and aid retina attachment and skin replacement and fertility.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: December 11, 2012
    Assignee: Genremedy LLC
    Inventors: Craig S. Atwood, Sivan Vadakkadath Meethal
  • Composition and method for treatment of tumors
    Patent number: 8329669
    Abstract: The present invention relates to a composition which is useful in the treatment of a tumor, a method for making such a composition, and a method for using such a composition. The invention relates also to a method for assaying for inhibitors of the activity of Core 1 protein and/or other proteins of the respiratory complex III of mitochondria.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: December 11, 2012
    Assignee: Sanofi
    Inventors: Paul August, Waan Jeng Huang, Sridaran Natesan, Soyan Lieberman
  • Compositions and methods for delivering RNAI using lipoproteins
    Patent number: 8324366
    Abstract: This invention relates to new compositions comprising at least one of a single or double stranded oligonucleotide, where said oligonucleotide has been conjugated to a lipophile and to which the conjugated oligonucleotide has been preassembled with lipoproteins. These compositions are effectively in delivering oligonucleotides to mammalian tissue where they effect gene silencing.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: December 4, 2012
    Assignees: Alnylam Pharmaceuticals, Inc., Eth Zurich
    Inventors: Akin Akinc, Tomoko Nakayama, Muthiah Manoharan, Markus Stoffel
  • USP47 inhibitors and methods to induce apoptosis
    Patent number: 8318437
    Abstract: The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: November 27, 2012
    Assignee: New York University
    Inventors: Michele Pagano, Jeffrey R. Skaar, Angelo Peschiaroli, N. Valerio Dorrello
  • Compositions and methods for inhibiting expression of huntingtin gene
    Patent number: 8314075
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: November 20, 2012
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Method for inhibiting scavenger receptor-A and increasing immune Response to antigens
    Patent number: 8314076
    Abstract: Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an immune response to an antigen by administering to an individual a composition containing antigen presenting cells that are characterized by specifically inhibited SR-A. Substantially purified populations of mammalian dendritic cells characterized by specifically inhibited SR-A are also provided.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: November 20, 2012
    Assignee: Health Research Inc.
    Inventors: Xiang-Yang Wang, John Subjeck
  • Therapeutic uses of inhibitors of RTP801
    Patent number: 8309532
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: November 13, 2012
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • Compositions and methods for inhibiting tumor growth and metastasis
    Patent number: 8304400
    Abstract: Disclosed are compositions and methods useful in the reduction of p11 protein activity in cancer cells. P11 protein is demonstrated to affect plasmin production and activity, MMP activity, plasminogen activation, antiangiogenic plasmin fragment production, cell invasion, tumor development and metastasis. Compositions that modulate levels of p11 either up or down are demonstrated to be effective in reducing tumor development. Also disclosed are cancer treatment methods that employ compositions that modulate p11 activity and clonal cell lines and assays useful for the identification of compositions that modulate p11 activity.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: November 6, 2012
    Inventor: David M. Waisman
  • Compositions and methods for decreasing type III deiodinase activity to modulate adiposity and blood glucose levels
    Patent number: 8304401
    Abstract: The present invention features methods for decreasing fat mass, increasing energy expenditure, increasing resistance to obesity, and lowering blood glucose levels in a subject with an agent that inhibits the expression or activity of type III deiodinase. In this regard, agents of the invention are useful in treating diabetes and obesity.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: November 6, 2012
    Assignee: Trustees of Dartmouth College
    Inventors: Donald L. St. Germain, Arturo Hernandez
  • siRNA hat inhibits WT1 gene expression and uses thereof
    Patent number: 8299234
    Abstract: The present inventors discovered that siRNAs targeting the 17AA site of the WT1 gene not only suppress the expression of the WT1 gene, but also demonstrate remarkable cell growth-suppressing effects and cell death-inducing effects in cancer cell lines.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: October 30, 2012
    Assignee: Haruo Sugiyama
    Inventors: Haruo Sugiyama, Yusuke Oji
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 8299039
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: October 30, 2012
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Limited
    Inventors: George Tachas, Kenneth W Dobie, Ravi Jain, Christopher I Belyea, Mark A Heffernan
  • Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers
    Patent number: 8288357
    Abstract: The present invention relates to a new use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers. More particularly, the present invention relates to a pharmaceutical composition for treating human cancers comprising BLT2 inhibitors and a method for treating human cancers using BLT2 inhibitors. The present inventors revealed the role of BLT2 as a survival factor of human cancers, such as bladder, prostate, pancreatic, and breast cancer and found that the BLT2 inhibitors can be used as anti-cancer drugs. The present inventors revealed that BLT2 has an important role in metastasis of cancer cells and angiogenesis of tumor and demonstrated that the anti-cancer activity of the BLT2 inhibitors is accomplished by inducing the apoptosis of cancer cells, inhibiting the metastasis of cancer cells, or inhibiting the angiogenesis of tumor.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: October 16, 2012
    Assignee: Korea University Research & Business Foundation
    Inventors: Jae-Hong Kim, Jung-A Choi, Eun-Young Kim, Geun-Young Kim, Chul-Min Kim, Ji-Min Seo, Hyun-Ju Kim, Jin-Wook Lee
  • MicroRNAs
    Patent number: 8288356
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 16, 2012
    Assignee: Santaris Pharma A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Inhibitors of TGF-R signaling for treatment of CNS disorders
    Patent number: 8283334
    Abstract: The present invention relates to the use of oligonucleotides for the preparation of a pharmaceutical composition for the prevention or treatment of a disease, wherein neurogenesis and/or neuroregeneration has a beneficial effect, in particular a disease like Morbus Alzheimer, Morbus Parkinson, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, Spinocerebellar Atrophies, Creutzfeldt Jakob Disease, Frontemporal Dementia, Morbus Pick, AIDS Dementia Complex, Vascular Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multisystem-Atrophy, Hallervorden Spatz Disease, Huntington's disease, Stroke, Traumatic Brain and spinal cord Injury, Retinitis Pigmentosa, Macular Degeneration, Glaucoma, Cochlea Degeneration, Depression, Schizophrenia, Multiple Sclerosis, and developmental neurodegeneration.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: October 9, 2012
    Inventors: Ulrich Bogdahn, Ludwig Aigner, Frank-Peter Wachs, Beate Winner, Jurgen Winkler
  • siRNA compounds for inhibiting NRF2
    Patent number: 8278287
    Abstract: The present invention provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: October 2, 2012
    Assignee: Quark Pharmaceuticals Inc.
    Inventors: Elena Feinstein, Igor Mett, Hagar Kalinski